Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Non-Current Assets (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Other Non-Current Assets for 12 consecutive years, with $102000.0 as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Assets fell 53.0% year-over-year to $102000.0; the TTM value through Mar 2026 reached $102000.0, down 53.0%, while the annual FY2025 figure was $102000.0, 53.0% down from the prior year.
  • Other Non-Current Assets hit $102000.0 in Q1 2026 for Syndax Pharmaceuticals, roughly flat from $102000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.0 million in Q1 2022 and bottomed at $102000.0 in Q4 2025.
  • Average Other Non-Current Assets over 5 years is $353062.5, with a median of $217000.0 recorded in 2023.
  • Year-over-year, Other Non-Current Assets skyrocketed 793.04% in 2022 and then tumbled 73.06% in 2024.
  • Syndax Pharmaceuticals' Other Non-Current Assets stood at $115000.0 in 2022, then soared by 302.61% to $463000.0 in 2023, then crashed by 53.13% to $217000.0 in 2024, then tumbled by 53.0% to $102000.0 in 2025, then changed by 0.0% to $102000.0 in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $102000.0, $102000.0, and $217000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.